[Renin-angiotensin-aldosterone system in the treatment of essential hypertension with a beta-adrenergic blocker: sotalol]. 1977

C Psadas, and G Sánchez, and H M Zaldívar, and J Rangel, and A Cuéllar, and P A Serrano

The administration of beta blockers has been useful in the treatment of essential hypertension. The anti-hypertensive effect of the beta-blocker sotalol was evaluated in 28 patients with essential hypertension. In all of the patients a determination of urinary aldosterone and plasma renin activity, before and after, three months of treatment with sotalol was done. In the pre-treatment tests, five patients (18%) had elevated renin values, in 13 (6%) renin was normal, and in 10 (36%) the renin activity in plasma was low. Treatment with sotalol caused normalization or significant lowering of diastolic pressure in the majority of cases with high or normal plasma renin. Patients with low plasma renin activity had less satisfactory results with the drug. Since there was no correlation between the lowering of arterial pressure and the degree of depletion of renin, we can conclude that anti-hypertensive mechanism of sotalol does not come from the decrease in secretion of renin. However our results suggest that patients with high renin respond better to treatment with sotalol, than cases with low renin levels.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000450 Aldosterone A hormone secreted by the ADRENAL CORTEX that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium. Aldosterone, (+-)-Isomer,Aldosterone, (11 beta,17 alpha)-Isomer
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D013015 Sotalol An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. Darob,MJ-1999,Sotalol Hydrochloride,Sotalol Monohydrochloride,MJ 1999,MJ1999

Related Publications

C Psadas, and G Sánchez, and H M Zaldívar, and J Rangel, and A Cuéllar, and P A Serrano
May 1975, Horumon to rinsho. Clinical endocrinology,
C Psadas, and G Sánchez, and H M Zaldívar, and J Rangel, and A Cuéllar, and P A Serrano
November 1973, Nihon rinsho. Japanese journal of clinical medicine,
C Psadas, and G Sánchez, and H M Zaldívar, and J Rangel, and A Cuéllar, and P A Serrano
April 1975, Medizinische Klinik,
C Psadas, and G Sánchez, and H M Zaldívar, and J Rangel, and A Cuéllar, and P A Serrano
January 1975, Kardiologia polska,
C Psadas, and G Sánchez, and H M Zaldívar, and J Rangel, and A Cuéllar, and P A Serrano
September 2011, Nihon rinsho. Japanese journal of clinical medicine,
C Psadas, and G Sánchez, and H M Zaldívar, and J Rangel, and A Cuéllar, and P A Serrano
January 1980, Giornale italiano di cardiologia,
C Psadas, and G Sánchez, and H M Zaldívar, and J Rangel, and A Cuéllar, and P A Serrano
September 1977, Revista clinica espanola,
C Psadas, and G Sánchez, and H M Zaldívar, and J Rangel, and A Cuéllar, and P A Serrano
April 1987, Recenti progressi in medicina,
C Psadas, and G Sánchez, and H M Zaldívar, and J Rangel, and A Cuéllar, and P A Serrano
January 1988, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!